<DOC>
	<DOCNO>NCT02320396</DOCNO>
	<brief_summary>This efficacy safety study desloratadine ( MK-4117 ) Japanese participant seasonal allergic rhinitis ( SAR ) . The primary hypothesis study change Baseline Total Nasal Symptom Score ( TNSS ) improve desloratadine compare placebo .</brief_summary>
	<brief_title>Efficacy Safety Study Desloratadine ( MK-4117 ) Japanese Participants With Seasonal Allergic Rhinitis ( MK-4117-204 )</brief_title>
	<detailed_description>This study consist one-week Symptom Confirmation Period participant undergo single-blinded placebo run-in , two-week double-blind Treatment Period two-week Follow-up Period .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<mesh_term>Desloratadine</mesh_term>
	<criteria>Has least 2year history seasonal allergic rhinitis typical symptom Male female unlikely conceive : surgically sterilize female , female reach natural menopause , reproductive potential agree either remain abstinent use ( partner use ) 2 acceptable method birth control study start 14 day last dose study drug . Has low respiratory tract infection nasopharyngolaryngeal infection ( acute upper respiratory tract infection , acute pharyngolaryngitis , acute tonsillitis , etc . ) require treatment Has coexisting infection systemic mycosis effective antibiotic Has asthma treatment and/or uncontrolled Has nasal septum ulcer , nasal surgery , nasal trauma heal Has vasomotor rhinitis eosinophilic rhinitis Has history hypersensitivity antihistamines ingredient study drug Has treatment corticosteroid ( oral , injectable , suppository , depot drug [ injectable ] ) immunological drug within 28 day prior Visit 2 Is currently receive treatment another investigational drug receive investigational drug within prior 3 month Has start specific desensitization therapy ( allergen immunotherapy ) nonspecific allassotherapy ( Histaglobin , vaccine therapy , etc . ) receive therapy within prior 3 month Has receive coagulation resection use laser therapy etc . treatment nasal symptom Will receive nasal nebulizer therapy and/or thermotherapy study period Has severe hepatic , renal , cardiac , hematological disease , serious coexisting disease whose general condition poor Has history malignancy clinically important hematological disorder , except adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix Has history severe drug allergy ( e.g . anaphylactoid reaction ) Is pregnant lactating may pregnant Is plan remote trip 1 day Symptom Confirmation Period 2 day Treatment Period .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>